Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptra to address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss. This data reinforces that this treatment regimen can effectively improve facial aesthetic appearance with high patient satisfaction over nine months.
Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude. Patients may experience facial changes such as dry, dull or sagging skin, a gaunt or hollowed-out facial appearance, or other unwelcome alterations to facial structure and balance. Results at nine months demonstrated that the combination of Sculptra and Restylane Lyft or Contour effectively improved the aesthetic appearance of patients experiencing facial volume loss associated with medication-driven weight loss, further supporting the benefits of the SHAPE Up HIT. "These results really reinforce the role of aesthetic treatments, like Sculptra and Restylane, in supporting patients through their weight loss transformations, showing they can deliver visible improvements in skin quality while also significantly enhancing patient satisfaction and emotional wellbeing," says Michael Somenek, M.D., clinical trial investigator. "The findings empower clinicians with data-backed tools to holistically address the nuanced aesthetic needs that arise with medication-driven weight loss, marking a pivotal moment where science meets patient-centered care."
For more information, visit the Galderma website.